Venous Thromboembolism

News Venous Thromboembolism

• ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402

  ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer), an oral anticoagulant.  The study showed that the incidence of venous thromboembolism (VTE) was simil more

• ThromboGenics and BioInvent Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism (VTE) Prophylaxis

  ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 (Anti-Factor VIII) for the prophylaxis of venous thromboembolism (VTE) after total hip surgery.The Phase IIb study more

• Positive TB-402 (Anti-Factor VIII Antibody) Phase II Data Published in Journal of Thrombosis and Haemostasis

  ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 (Anti-Factor VIII) Phase II trial results, evaluating the product’s efficacy and safety for the prevention of venous thromboembolism (VTE) after orthopaedic surgery, have been published in the more

Publications Venous Thromboembolism

• A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium

  ABSTRACT Venous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we cond more

• Proteomic analysis of venous thromboembolism: an update

  Venous thromboembolism is a complex, multifactorial disorder, the pathogenesis of which typically involves a variety of inherited or acquired factors. The multifactorial etiology of this disease and the partial correlation between genotype and prothrombotic phenotype limit greatly the value of genet more

• Dosing time‐dependent influence of raloxifene on plasma plasminogen activator inhibitor‐1 concentration in postmenopausal women with osteoporosis

  Abstract Raloxifene, a selective oestrogen receptor modulator commonly used for the treatment of postmenopausal osteoporosis, affects the coagulation and fibrinolytic systems and consequently increases the risk of venous thromboembolism. Because both the coagulation and fibrinolytic systems ex more

Market studies Venous Thromboembolism

• Venous Thromboembolism – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Venous Thromboembolism - Pipeline Review, H1 2012', provides an overview of the Venous Thromboembolism therapeutic pipeline. This report provides information on the therapeutic development for Venous Thromboembolism, complete with latest updates, and special more

• Venous Thromboembolism – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Venous Thromboembolism - Pipeline Review, H2 2012', provides an overview of the Venous Thromboembolism therapeutic pipeline. This report provides information on the therapeutic development for Venous Thromboembolism, complete with latest updates, and special more

• Venous Thromboembolism Global Clinical Trials Review, H1, 2012

  Introduction GlobalData's clinical trial report, “Venous Thromboembolism Global Clinical Trials Review, H1, 2012" provides data on the Venous Thromboembolism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Venous Thromboembolism. It in more

Websites Venous Thromboembolism